Literature DB >> 24574838

Duodenal adenocarcinoma following a neuroendocrine tumor in the duodenum.

Bun Kim1, Ji Hye Huh1, Youngsook Kim1, Moon Jae Chung1, Jeong Youp Park1, Si Young Song2, Seung Woo Park1.   

Abstract

Primary duodenal adenocarcinoma is a rare malignant neoplasm accounting for 0.3% of all gastrointestinal tract carcinomas. We herein present one case of duodenal adenocarcinoma after duodenal neuroendocrine carcinoma. Poorly differentiated duodenal neuroendocrine carcinoma with liver metastasis (TxNxM1) was confirmed, and eight cycles of palliative chemotherapy (5-fluorouracil/etoposide/cisplatin) were administered. The patient was then in a clinically complete response status. About 1 year later, newly developed adenocarcinoma was detected at the same site. It was completely surgically resected, and the patient was cured.

Entities:  

Keywords:  Drug therapy; Duodenal neoplasms; Neuroendocrine tumors

Mesh：

Substances：

Year:  2014        PMID： 24574838      PMCID： PMC3932400          DOI： 10.3904/kjim.2014.29.1.96

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN： 1226-3303            Impact factor:   2.884


  9 in total

Review 1.  Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract.

Authors:  G Rindi; C Capella; E Solcia
Journal:  Q J Nucl Med       Date:  2000-03

2.  Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic).

Authors:  Ola Nilsson; Erik Van Cutsem; Gianfranco Delle Fave; James C Yao; Marianne E Pavel; Anne M McNicol; M I Sevilla Garcia; Wolfram H Knapp; Fahrettin Keleştimur; Alain Sauvanet; Stanislas Pauwels; Dik J Kwekkeboom; Martyn Caplin
Journal:  Neuroendocrinology       Date:  2007-02-20       Impact factor: 4.914

3.  A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990.

Authors:  J S Chow; C C Chen; H Ahsan; A I Neugut
Journal:  Int J Epidemiol       Date:  1996-08       Impact factor: 7.196

4.  Incidence and management of primary malignant small bowel cancers: a well-defined French population study.

Authors:  Côme Lepage; Anne-Marie Bouvier; Sylvain Manfredi; Vincent Dancourt; Jean Faivre
Journal:  Am J Gastroenterol       Date:  2006-10-06       Impact factor: 10.864

5.  Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management.

Authors:  Hans Scherübl; Robert T Jensen; Guillaume Cadiot; Ulrich Stölzel; Günter Klöppel
Journal:  World J Gastrointest Endosc       Date:  2010-10-16

6.  Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.

Authors:  A Zaanan; L Costes; M Gauthier; D Malka; C Locher; E Mitry; D Tougeron; T Lecomte; J-M Gornet; I Sobhani; V Moulin; P Afchain; J Taïeb; F Bonnetain; T Aparicio
Journal:  Ann Oncol       Date:  2010-03-11       Impact factor: 32.976

7.  A single-institution experience with 491 cases of small bowel adenocarcinoma.

Authors:  Thorvardur R Halfdanarson; Robert R McWilliams; John H Donohue; J Fernando Quevedo
Journal:  Am J Surg       Date:  2010-06       Impact factor: 2.565

8.  Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.

Authors:  Bouthaina S Dabaja; Dima Suki; Barbara Pro; Mark Bonnen; Jaffer Ajani
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

9.  Small bowel cancer in western Canada.

Authors:  S Gabos; J Berkel; P Band; D Robson; H Whittaker
Journal:  Int J Epidemiol       Date:  1993-04       Impact factor: 7.196
  9 in total
  1 in total

1.  Case of a tumor comprising gastric cancer and duodenal neuroendocrine tumor.

Authors:  Hiroaki Kaneko; Akio Miyake; Yasuaki Ishii; Soichiro Sue; Haruo Miwa; Tomohiko Sasaki; Toshihide Tamura; Masaaki Kondo; Shin Maeda
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.